title: Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography.
authors.forename: Lauren
authors.initials: L
authors.lastname: Branchini
authors.forename: Caio
authors.initials: C
authors.lastname: Regatieri
authors.forename: Mehreen
authors.initials: M
authors.lastname: Adhi
authors.forename: Ignacio
authors.initials: I
authors.lastname: Flores-Moreno
authors.forename: Varsha
authors.initials: V
authors.lastname: Manjunath
authors.forename: James G
authors.initials: JG
authors.lastname: Fujimoto
authors.forename: Jay S
authors.initials: JS
authors.lastname: Duker
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002829:Choroid / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D009929:Organ Size; D000069579:Ranibizumab; D019233:Retreatment; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab